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Objectives: To determine the association between
Toxoplasma gondii infection and Parkinson’s disease
and to investigate whether T. gondii seropositivity is
associated with the general characteristics of patients
with Parkinson’s disease.
Design: Case–control study.
Setting: Cases and controls were enrolled in Durango
City, Mexico.
Participants: 65 patients with Parkinson’s disease
and 195 age- and gender-matched control subjects
without Parkinson’s disease.
Primary and secondary outcome measures:
Serum samples of participants were analysed for anti-
T. gondii IgG and IgM antibodies by commercially
available enzyme-linked immunoassays. Prevalence of
T. gondii DNA was determined in seropositive subjects
using PCR. The association between clinical data and
infection was examined by bivariate analysis.
Results: Anti-T. gondii IgG antibodies were found in
6/65 cases (9.2%) and in 21/195 controls (10.8%)
(OR 0.84; 95% CI 0.32 to 2.18; p=0.81). The
frequency of high (>150 IU/mL) antibody levels was
similar among cases and controls (p=0.34). None of
the anti-T. gondii IgG positive cases and four of the
anti-T. gondii IgG positive controls had anti-T. gondii
IgM antibodies (p=0.54). The prevalence of T. gondii
DNA was comparable in seropositive cases and
controls (16.7% and 25%, respectively; p=1.0).
Seroprevalence of T. gondii infection was associated
with a young age onset of disease (p=0.03), high
Unified Parkinson Disease Rating Scale scores
(p=0.04) and depression (p=0.02). Seropositivity to
T. gondii infection was lower in patients treated with
pramipexole than in patients without this treatment
(p=0.01). However, none of the associations remained
significant after Bonferroni correction.
Conclusions: The results do not support an
association between T. gondii infection and Parkinson’s
disease. However, T. gondii infection might have an
influence on certain symptoms of Parkinson’s disease.
Further research to elucidate the role of T. gondii
exposure on Parkinson’s disease is warranted.
INTRODUCTION
Toxoplasma gondii (T. gondii) is an
Apicomplexan parasite of medical import-
ance.1 Infections with T. gondii are common
and occur worldwide.2 The main routes of
human infection with T. gondii include inges-
tion of water or food contaminated with
parasite oocysts shed by cats and consump-
tion of raw or undercooked meat containing
parasite tissue cysts.3 In rare cases, transmis-
sion of T. gondii may occur by blood transfu-
sion or transplantation.4 T. gondii spreads to
a number of organs of the infected host and
is able to cross biological barriers and enter
into the brain, eye and placenta.5 Primary
infection with T. gondii during pregnancy
may lead to infection of the fetus.6 The clin-
ical spectrum of T. gondii infection varies
from asymptomatic to severe disease with
lymphadenopathy, chorioretinitis and
meningoencephalitis.3 6 7
Infection with T. gondii has been linked to
a number of neuropsychiatric diseases
including schizophrenia, Parkinson’s
disease and Alzheimer’s disease, and the
Strengths and limitations of this study
▪ This study provides evidence for a better un-
derstanding on the association of Toxoplasma
gondii infection and Parkinson’s disease.
▪ This is the first study that adds molecular
detection of T. gondii to assess its link with
Parkinson’s disease.
▪ Matching by age and sex was performed.
▪ This study provides clinical characteristics of
Parkinson’s disease associated with T. gondii
infection.
▪ The seroprevalence of T. gondii infection was
low.
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neurobiological data of this link have recently been
reviewed.8 The aetiology of Parkinson’s disease is largely
unknown; however, progressive impairment of voluntary
motor control—which is a clinical feature of this disease
—is caused by a loss of midbrain substantia nigra dopa-
mine neurons.9 Tissue cysts of T. gondii may be found in
all brain areas,10 and T. gondii may lead to neurological
damage.11 It therefore raises the question whether infec-
tion with T. gondii may lead to Parkinson’s disease. On
the other hand, infection with T. gondii may increase the
production of dopamine in the brain.12 Therefore, it
also raises the question whether Parkinson’s disease
could be negatively associated with infection with
T. gondii. However, the potential link of T. gondii infec-
tion and Parkinson’s disease has been poorly in-
vestigated, and conﬂicting results about the association
of T. gondii exposure and Parkinson’s disease have been
reported. Miman et al13 found a signiﬁcantly higher rate
of anti-T. gondii IgG antibodies in patients with
Parkinson’s disease than in controls. In contrast, Celik
et al14 15 found similar seropositivity rates to T. gondii in
50 patients with idiopathic Parkinson’s disease and 50
healthy volunteers. In addition, Oskouei et al16 found
similar prevalences of anti-T. gondii IgG antibodies in
75 patients with Parkinson’s disease and 75 controls.
Given these conﬂicting results, we assessed the associ-
ation of T. gondii infection and Parkinson’s disease in a
cohort of patients attending public hospitals in Durango
City, Mexico. In addition, we investigated the association
of T. gondii seropositivity and the sociodemographic and
clinical characteristics of patients with Parkinson’s
disease.
MATERIALS AND METHODS
Patients with Parkinson’s disease and controls
We performed a case–control study of 65 patients with
Parkinson’s disease (cases) and 195 control subjects.
Diagnosis of Parkinson’s disease was made using the UK
Parkinson’s Disease Society brain bank clinical diagnos-
tic criteria.17 Patients were enrolled in the departments
of neurology at two public hospitals: the Hospital
‘Santiago Ramón y Cajal’ of the Institute of Security and
Social Services for the State Workers, and the Hospital
‘450’ of the Secretary of Health in Durango City,
Mexico. Serum samples were obtained from January to
December 2014. Inclusion criteria for the cases were
patients with Parkinson’s disease of either sex who volun-
tarily accepted to participate in the study. Exclusion cri-
teria for the cases were presence of renal or liver
diseases, gout, alcoholism, history of cerebrovascular
disease or other neurological diseases, and use of acetyl-
salicylic acid or allopurinol. Cases were aged 39–95 years
(mean 69.08±11.39 years) and included 30 men and 35
women. We used a convenience sampling to enrol cases.
Inclusion criteria for controls were subjects from the
general population of the same city without neurological
disease, matched with cases by age and sex. We included
three controls per case. Controls were aged 38–91 years
(mean 68.56±10.08 years) and included 90 men and 105
women. There was no difference in age between cases
and controls (p=0.85).
Sociodemographic and clinical data of cases
We obtained the sociodemographic and clinical data of
the patients with Parkinson’s disease through face-to-face
neurological consultations and with the aid of a ques-
tionnaire. Since the correlation of T. gondii infection
with clinical features of Parkinson’s disease is largely
unknown, we explored the association between T. gondii
seropositivity and a number of clinical characteristics dir-
ectly or indirectly associated with Parkinson’s disease.
Sociodemographic data obtained included age and sex.
Clinical data included Hoehn and Yahr stages,18 Uniﬁed
Parkinson Disease Rating Scale scores, age at onset of
Parkinson’s disease, duration of disease, presence of
tremor or rigidity at disease onset, most affected body
side, familial history of Parkinson’s disease, presence of
hyposmia, syncope, paraesthesias, dementia, impair-
ments of memory and vision, depression, anxiety, sialor-
rhoea, constipation, weight loss, sleep disorders, erectile
dysfunction and orthostatic hypotension. In addition,
information about the presence of obesity, dyslipidae-
mia, diabetes mellitus, arterial hypertension, smoking,
diarrhoea, nausea and/or vomiting was obtained from
each patient. Antiparkinsonian medication was also
registered and included the use of levodopa, carbidopa,
pramipexole, trihexyphenidyl, biperiden, amantadine,
rasagiline, selegiline, azilect, rotigotine and bromocrip-
tine. The occurrence of dyskinesia, urinary incontinence
and motor ﬂuctuations (ie, end-of-dose wearing-off,
unpredictable off, delay on and no on) related to treat-
ment was also recorded.
Detection of anti-T. gondii antibodies
Anti-T. gondii IgG antibodies were detected in the serum
of participants using the commercially available enzyme
immunoassay Toxoplasma IgG kit (Diagnostic Automation,
Woodland Hills, California, USA). This test determines the
presence and also the levels of IgG antibodies. A cut-off of
8 IU/mL of speciﬁc anti-T. gondii IgG antibody was used.
All serum samples positive for anti-T. gondii IgG antibodies
were further analysed for anti-T. gondii IgM antibodies
by the commercially available enzyme immunoassay
Toxoplasma IgM kit (Diagnostic Automation). All tests were
performed following the manufacturer’s instructions.
Detection of T. gondii DNA by PCR
Whole blood samples of cases and controls with
anti-T. gondii IgG antibodies were further examined to
detect T. gondii DNA by nested PCR. Whole blood
extraction of DNA followed the protocol described by
Iranpour and Esmailizadeh (http://www.protocol-online.
org/prot/Protocols/Rapid-Extraction-of-High-Quality-DNA-
from-Whole-Blood-Stored-at-4-C-for-Long-Period-4175.html).
A PCR protocol with two pairs of primers directed
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against the B1 gene of T. gondii was used, as previously
described.19 The ampliﬁed PCR products were detected
using gel electrophoresis, stained with ethidium bromide
and visualised under ultraviolet light.
Statistical analysis
We used the software Microsoft Excel 2010, Epi Info V.7
(Centers for Disease Control and Prevention: http://
wwwn.cdc.gov/epiinfo/) and SPSS V.15.0 (SPSS,
Chicago, Illinois, USA) to analyse the results. For calcula-
tion of the sample size we used a 95% conﬁdence level,
power of 80%, 1:3 proportion of cases and controls and
a reference seroprevalence of 12.0%20 as the expected
frequency of exposure in controls. The result of the
sample size calculation was 60 cases and 179 controls. To
avoid bias, we excluded subjects with missing clinical
data. Age values among the groups were compared with
the paired Student’s t-test. The Fisher exact test was used
to evaluate the association between seropositivity to
T. gondii and the characteristics of the patients. ORs and
95% CIs were calculated and a p value <0.05 was consid-
ered statistically signiﬁcant. Bonferroni correction was
applied for adjustment of multiple testing.
RESULTS
Anti-T. gondii IgG antibodies were found in 6/65 cases
(9.2%) and in 21/195 controls (10.8%) (OR 0.84; 95%
CI 0.32 to 2.18; p=0.81). Of the six anti-T. gondii IgG
positive cases, ﬁve (83.3%) had anti-T. gondii IgG anti-
body levels >150 IU/mL and one (16.7%) 12 IU/mL. In
contrast, of the 21 anti-T. gondii IgG positive controls, 11
(52.4%) had anti-T. gondii IgG antibody levels >150 IU/
mL, one (4.8%) between 100 to 150 IU/mL and 9
(42.8%) between 8 and 99 IU/mL. The frequency of
high (>150 IU/mL) antibody levels was similar among
cases and controls (p=0.34). None of the six
anti-T. gondii IgG positive cases had anti-T. gondii IgM
antibodies whereas four (19.0%) of the 21 anti-T. gondii
IgG positive controls had anti-T. gondii IgM antibodies.
There was no difference in the rate of IgM seropositivity
among cases and controls (p=0.54). Anti-T. gondii IgG
antibodies were detected in four (11.4%) of 35 female
cases and in seven (6.7%) of 105 female controls (OR
1.80; 95% CI 0.49 to 6.58; p=0.46), whereas anti-T. gondii
IgG antibodies were detected in two (6.7%) of 30 male
cases and in 14 (15.6%) of 90 male controls (OR 0.38;
95% CI 0.08 to 1.81; p=0.35). The frequency of high
(>150 IU/mL) anti-T. gondii IgG antibody levels was
similar in male and female cases (2/30 (6.7%) and 3/35
(8.6%), respectively, p=1.00). Seroprevalence of T. gondii
infection was similar among cases and controls of several
age groups (table 1). One (16.7%) of the six cases sero-
positive to T. gondii IgG antibodies was positive for
T. gondii DNA by PCR. We were able to test 20 of 21 con-
trols seropositive to T. gondii IgG antibodies. Five (25%)
of these 20 controls were positive for T. gondii DNA by
PCR. The prevalence of T. gondii DNA was similar in
cases and controls (p=1.0).
With respect to clinical characteristics of patients, sero-
prevalence of T. gondii infection was higher in patients
with an onset of Parkinson’s disease at a young age
(≤40 years) than in those with a disease onset at older
ages (p=0.03). Table 2 shows a selection of clinical
characteristics of patients with Parkinson’s disease and
their correlation with T. gondii seropositivity.
Seroprevalence of infection with T. gondii was also
higher in patients with higher Uniﬁed Parkinson
Disease Rating Scale scores (88–136) than in those with
lower scores (p=0.04). Seropositivity to T. gondii was
observed in six (17.1%) of 35 patients suffering from
depression but in none of 30 patients without depres-
sion (p=0.02). Other clinical characteristics of patients
including Hoehn and Yahr stages, duration of disease,
presence of tremor or rigidity at disease onset, most
affected body side, familial history of Parkinson’s
disease, presence of hyposmia, syncope, paraesthesias,
dementia, impairments of memory and vision, anxiety,
sialorrhoea, constipation, weight loss, sleep disorders,
erectile dysfunction, and orthostatic hypotension did not
show an association with T. gondii seropositivity. In add-
ition, T. gondii exposure was not associated with the pres-
ence of obesity, dyslipidaemia, diabetes mellitus, arterial
hypertension, smoking, diarrhoea, nausea and/or vomit-
ing in the patients. Seropositivity to T. gondii infection
was signiﬁcantly (p=0.01) lower in patients receiving pra-
mipexole than in patients not treated with this drug
(table 2). Seroprevalence of infection was similar in
patients regardless of the use of other antiparkinsonian
medications including levodopa, carbidopa, trihexyphe-
nidyl, biperiden, amantadine, rasagiline, selegiline,
azilect, rotigotine and bromocriptine. The presence of
Table 1 Comparison of IgG seropositivity rates in cases and controls according to age groups
Cases Controls
p Value
Subjects tested Seropositive Subjects tested Seropositive
N N % N N %
Age groups
≤40 years 2 1 50 6 0 0 0.25
41–60 years 12 1 8.3 22 1 4.5 1.00
61–80 years 41 4 9.8 144 17 11.8 1.00
>80 years 10 0 0 23 3 13 0.53
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dyskinesia, urinary incontinence and motor ﬂuctuations
(end-of-dose wearing-off, unpredictable off, delay on
and no on) did not correlate with T. gondii infection.
None of the associations between clinical data and T. gondii
seropositivity remained signiﬁcant after Bonferroni
correction.
Table 2 Bivariate analysis of clinical data and infection with Toxoplasma gondii in patients with Parkinson’s disease
Characteristic
Subjects tested
Prevalence of T. gondii
infection
p ValueN N %
Age at Parkinson onset
≤40 years 4 2 50 0.03
>40 years 61 4 6.6
Duration of disease
≤10 years 57 5 8.8 0.56
>10 years 8 1 12.5
Tremorigenic type
Yes 49 5 10.2 1.00
No 16 1 6.3
Rigid type
Yes 25 3 12 0.66
No 40 3 7.5
Hoehn and Yahr stages
0 5 0 0 0.59
1 17 3 17.6
2 14 1 7.1
3 20 1 5
4 5 1 20
5 4 0 0
Unified Parkinson disease rating scores
0–87 55 3 5.5 0.04
88–136 10 3 30
Constipation
Yes 29 4 13.8 0.39
No 36 2 5.6
Syncope
Yes 6 1 16.7 0.45
No 59 5 8.5
Paraesthesias
Yes 12 3 25 0.07
No 53 3 5.7
Weight loss
Yes 27 4 14.8 0.22
No 38 2 5.3
Dementia
Yes 23 3 13 0.65
No 42 3 7.1
Depression
Yes 35 6 17.1 0.02
No 30 0 0
Anxiety
Yes 30 4 13.3 0.40
No 35 2 5.7
Vision impairment
Yes 22 3 13.6 0.39
No 43 3 7
Dyskinesia
Yes 21 3 14.3 0.37
No 44 3 6.8
Use of pramipexole
Yes 43 1 2.3 0.01
No 22 5 22.7
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DISCUSSION
T. gondii is an intracellular parasite and can persist in
neurons, modifying their function and structure.21 Cysts
of T. gondii can be found throughout the brain,10 and
this parasite alters dopamine metabolism.21 Thus, it
raises the question whether infection with T. gondii has
any link with a dopamine-related neurological disease.
There is controversy concerning the association of
T. gondii infection and Parkinson’s disease. The number
of reports about this association is very small. We there-
fore sought to determine the association between
T. gondii seropositivity and patients with Parkinson’s
disease in the northern Mexican city of Durango. This
age- and gender-matched case–control seroprevalence
study showed similar frequencies of T. gondii infection in
cases and controls. Similarly, we did not ﬁnd differences
in the frequency of high levels of anti-T. gondii IgG
antibodies, IgM seropositivity rates and prevalence of
T. gondii DNA among cases and controls. The 9.2% sero-
prevalence found in patients with Parkinson’s disease
is comparable to the 12% seroprevalence of T. gondii
infection reported in elderly people20 and 13.3% in
patients with liver disease22 in the same Durango City. In
contrast, the seroprevalence found in patients with
Parkinson’s disease is lower than seroprevalences
reported in other population groups in Durango City
including 15.4% in female sex workers,23 20% in schizo-
phrenic patients24 and 21.1% in inmates25 and waste
pickers.26 Therefore, the results of our study do not
support an association between T. gondii infection and
Parkinson’s disease. The lack of association between
T. gondii infection and the presence of Parkinson’s
disease is consistent with similar results reported by
Celik et al14 15 and Oskouei et al.16
In contrast, our results conﬂict with those reported by
Miman et al13 who found a signiﬁcantly higher sero-
prevalence of anti-T. gondii IgG antibodies in patients
with Parkinson’s disease than in controls. Other studies
have also linked toxoplasmosis with Parkinson’s disease.
For instance, in 1992 Noël et al27 reported hemichorea
and parkinsonism in two AIDS patients with cerebral
toxoplasmosis. Basal ganglia, which are involved in the
control of voluntary motor movements, can be affected
in cerebral toxoplasmosis, as reported in patients with
AIDS,28–30 a patient with acute myeloid leukaemia
undergoing two allogenic stem cell transplantations,31
an immunocompromised female renal transplant recipi-
ent32 and a non-immunocompromised pregnant
woman.33 Improvement of parkinsonism in an AIDS
patient with cerebral toxoplasmosis was achieved after
anti-T. gondii and antiretroviral therapies.34 Infection
with T. gondii has been associated with elevated levels of
dopamine within dopaminergic cells,12 whereas an
important feature of Parkinson’s disease is the loss of
dopamine-producing neurons.35 However, the inter-
action of T. gondii and neurons in patients with
Parkinson’s disease is largely unknown. It raises the ques-
tion whether dopamine production during infection
with T. gondii is too low to compensate for the deﬁcit of
dopamine and to induce a clinical improvement in
patients with Parkinson’s disease. Further research to elu-
cidate the role of dopamine produced during T. gondii
infection on neurons of patients with Parkinson’s disease
is needed.
Interestingly, the frequency of T. gondii infection was
higher in patients with onset of Parkinson’s disease at a
young age than in those with a disease onset at older
ages. It is not clear why T. gondii infection was associated
with a young onset of Parkinson’s disease. This young
onset of disease is less common than middle and late
onsets, and patients with young onset have a long sur-
vival and suffer from depression more frequently than
patients with older onset of disease.36 Remarkably, we
found that seropositivity to T. gondii was associated with
depression in the patients with Parkinson’s disease
studied. To the best of our knowledge, this is the ﬁrst
report of an association between T. gondii exposure and
depression in patients with Parkinson’s disease.
Infection with T. gondii has been linked to depression in
other population groups, such as women veterans37 and
pregnant women.38 However, other studies including a
meta-analysis of 50 studies of psychiatric patients and
healthy controls,39 a cross-sectional internet study on a
non-clinical population of 5535 subjects40 and the third
National Health and Nutrition Survey in the USA41 have
not found a correlation between T. gondii infection and
depression
Of note, seroprevalence of T. gondii infection corre-
lated with high Uniﬁed Parkinson Disease Rating Scale
scores. In a search for this association in the medical lit-
erature, no reports were found. This association suggests
that T. gondii infection might have an inﬂuence on clin-
ical characteristics of patients with Parkinson’s disease. It
is possible that T. gondii does not associate per se with
the presence of Parkinson’s disease because of the
opposite relations with dopamine production—that is,
T. gondii infection induces an increase in dopamine pro-
duction whereas Parkinson’s disease is related to a
decrease in dopamine production. However, infection
with T. gondii might be involved in the appearance of
symptoms found in patients with Parkinson’s disease
such as depression. Further research on the inﬂuence of
T. gondii infection on signs and symptoms of Parkinson’s
disease should be conducted.
We also observed that seropositivity to T. gondii infec-
tion was signiﬁcantly lower in patients treated with pra-
mipexole than in those not receiving this treatment.
This ﬁnding suggests a protective effect of pramipexole
for T. gondii infection. It is not clear why pramipexole
users had a low frequency of T. gondii infection. No
anti-T. gondii activity of pramipexole has been reported.
Further research to elucidate the negative association of
pramipexole with T. gondii infection is needed.
This study has limitations. The sample size was small.
Further studies with larger sample sizes should be con-
ducted. The low number of cases seropositive for
Open Access
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T. gondii did not allow us to perform multivariate analysis
to determine the association between patient character-
istics and seropositivity to T. gondii. In addition, the asso-
ciations between clinical data and T. gondii seropositivity
found in this study should be interpreted with care,
since the statistical power of comparisons was low
(<0.80) and no associations remained statistically signiﬁ-
cant after Bonferroni correction.
CONCLUSIONS
The results obtained in a cohort of patients in Durango,
Mexico do not support an association between T. gondii
infection and Parkinson’s disease. However, the results
suggest that T. gondii infection might inﬂuence the
symptoms of Parkinson’s disease. Further research to
elucidate the role of T. gondii exposure on the clinical
characteristics of Parkinson’s disease is therefore
needed.
Author affiliations
1Faculty of Medicine and Nutrition, Biomedical Research Laboratory, Juárez
University of Durango State, Durango, Mexico
2Institute for Scientific Research “Dr. Roberto Rivera-Damm”, Juárez
University of Durango State, Durango, Mexico
3General Hospital “450”, Secretary of Health, Durango, Mexico
4Unidad de Trastornos del Movimiento y Sueño, Hospital General Dr Manuel
Gea González, Ciudad de México, México, Mexico
5Institute for Microbiology and Hygiene, Campus Benjamin Franklin, Charité
Medical School, Hindenburgdamm 27, Berlin, Germany
6Roche Molecular Diagnostics, Pleasanton, California, USA
7Hospital Santiago Ramón y Cajal, Instituto de Seguridad y Servicios Sociales
de los Trabajadores del Estado, Durango, Mexico
Contributors CA-E designed the study protocol, performed the laboratory
tests and data analysis and wrote the manuscript. EMM-H, JMS-P, LAR-C and
AAS-C obtained the blood samples and clinical dat, and performed the data
analysis. JH-T, OA-C, LFS-A, FXC-J and OL performed the data analysis and
wrote the manuscript. All authors read and approved the final version of the
manuscript.
Funding This study was financially supported by Juarez University of
Durango State.
Competing interests None declared.
Patient consent Obtained.
Ethics approval This study was approved by the Ethics Committees of the
General Hospital of the Secretary of Health and the Institute of Security and
Social Services for the State Workers, Durango, Mexico.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Arisue N, Hashimoto T. Phylogeny and evolution of apicoplasts and
apicomplexan parasites. Parasitol Int 2015;64:254–9.
2. Dubey JP. The history of Toxoplasma gondii—the first 100 years.
J Eukaryot Microbiol 2008;55:467–75.
3. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet
2004;363:1965–76.
4. Barsoum RS. Parasitic infections in transplant recipients. Nat Clin
Pract Nephrol 2006;2:490–503.
5. Harker KS, Ueno N, Lodoen MB. Toxoplasma gondii dissemination:
a parasite’s journey through the infected host. Parasite Immunol
2015;37:141–9.
6. Dubey JP. Toxoplasmosis of animals and humans. Boca Raton, FL:
2nd edn. CRC Press, 2010.
7. Maenz M, Schlüter D, Liesenfeld O, et al. Ocular toxoplasmosis
past, present and new aspects of an old disease. Prog Retin Eye
Res 2014;39:77–106.
8. Fabiani S, Pinto B, Bonuccelli U, et al. Neurobiological studies on
the relationship between toxoplasmosis and neuropsychiatric
diseases. J Neurol Sci 2015;351:3–8.
9. Michel PP, Hirsch EC, Hunot S. Understanding dopaminergic cell
death pathways in Parkinson disease. Neuron 2016;90:675–91.
10. Kamerkar S, Davis PH. Toxoplasma on the brain: understanding
host-pathogen interactions in chronic CNS infection. J Parasitol Res
2012;2012:589295.
11. McConkey GA, Martin HL, Bristow GC, et al. Toxoplasma gondii
infection and behaviour—location, location, location? J Exp Biol
2013;216(Pt 1):113–19.
12. Martin HL, Alsaady I, Howell G, et al. Effect of parasitic infection on
dopamine biosynthesis in dopaminergic cells. Neuroscience
2015;306:50–62.
13. Miman O, Kusbeci OY, Aktepe OC, et al. The probable relation
between Toxoplasma gondii and Parkinson’s disease. Neurosci Lett
2010;475:129–31.
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